Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference

ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York.

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2014/98124275805.cfm. After the presentation, a replay will be archived and accessible for 30 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics’ website at www.therivabio.com.

SOURCE Synthetic Biologics, Inc.